<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496766</url>
  </required_header>
  <id_info>
    <org_study_id>GECP17/04_THOMAS</org_study_id>
    <secondary_id>2017-004822-13</secondary_id>
    <secondary_id>KO-IST-003</secondary_id>
    <nct_id>NCT03496766</nct_id>
  </id_info>
  <brief_title>Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS</brief_title>
  <official_title>An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Lung Cancer Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spanish Lung Cancer Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase II study consists of 2 parts: 1) pre-screening phase and 2) treatment phase.

      The pre-screening phase will investigate the presence of HRAS mutations in subjects with a
      histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer
      (SQ-NSCLC). Subjects may participate in the pre-screening phase at initial diagnosis or
      following prior lines of therapy for SQ-NSCLC.

      The treatment phase will investigate the antitumor activity in terms of ORR of tipifarnib in
      subjects with locally advanced squamous non-small cell lung cancer (SQ-NSCLC) with HRAS
      mutations and for whom there is no curative therapy available.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subject enrolment may proceed with information available on tumor HRAS status previously
      generated during the pre-screening phase, but all subjects must consent to provide tumor
      slides (or tumor tissue block) from a prior diagnostic biopsy for a retrospective testing of
      RAS gene status, including T81C polymorphism, and other potential biomarkers at a central
      facility.

      Tipifarnib will be administered at a starting dose of 900 mg, po, bid daily on days 1-7 and
      15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may
      continue to receive tipifarnib treatment for up to 24 months in the absence of disease
      progression and unmanageable toxicity. Treatment may continue beyond 24 months if there is
      documented evidence of continued clinical benefit. At the judgement of the investigator, the
      dose of tipifarnib may be increased to 1,200 mg.

      Tumor assessments will be performed at screening and approximately every 8 weeks for the
      first 6 months (cycles 2, 4, 6) and then every 12 weeks (cycles 9, 12, 15, etc.) until
      disease progression, starting at the end of Cycle 2. Additional tumor assessments may be
      conducted if deemed necessary by the Investigator or for a confirmation of an objective
      response. Subjects who discontinue tipifarnib treatment for reasons other than disease
      progression must continue tumor assessments until disease progression, withdrawal of
      subject's consent to study procedures or initiation of another anticancer therapy.

      Determination of objective tumor response will be performed by the Investigator according to
      the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1. Electronic copies of tumor
      images may be de-identified of subject's personal information at the clinical sites and
      collected by the Sponsor to undergo an external independent radiological review if the
      sponsor deems it necessary for the final assessment of treatment efficacy. Subjects with a
      solitary site of disease who have experienced a response may be considered for surgical
      resection. Subjects with a best response of a partial response and residual disease after
      salvage surgery will be eligible to continue on study therapy. Information on the duration of
      response to the last prior therapy will be collected.

      Upon disease progression, subjects will be followed approximately every 12 weeks for survival
      until either death or 24 months after accrual in the subject's study cohort has been
      completed, whichever occurs first. Information on subsequent anticancer therapy will be
      collected.

      All subjects will be followed-up for safety during treatment and for approximately 30
      additional days after treatment discontinuation (or until immediately before the
      administration of another anticancer treatment). Additional safety follow up may be conducted
      if unresolved toxicity is present at the End of Treatment visit.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 30, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>From the first dose until progression disease, assessed from the first dose until the first assessment at week 6 from the first dose</time_frame>
    <description>To determine the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, squamous non-small cell lung cancer (SQ-NSCLC) with HRAS mutations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of HRAS mutations</measure>
    <time_frame>at the beginning of the study, day -7 to day 0</time_frame>
    <description>As there is a screening phase where HRAS mutations will be analyzed, the second outcome is to determine the frequency (%) of this mutation in the target population of this study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability as Incidence of Treatment-Emergent Adverse Events of Tipifarnib</measure>
    <time_frame>from the first dose of treatment until 30 days after the last dose of treatment</time_frame>
    <description>Adverse events will be collected in all the patients in order to now the tolerability of the treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tipifarnib 900 mg, po, bid daily on days 1-7 and 15-21 of 28-day treatment cycles for up to 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipifarnib</intervention_name>
    <description>Tipifarnib 900 mg will be administered until progression</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Zarnestra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has a histologically or cytologically confirmed diagnosis of squamous
             non-small cell lung cancer (SQ-NSCLC) for which there is no curative therapy
             available.

          2. Subject has relapsed (progressive disease) or is refractory to one or more prior
             therapies. In the case of therapy received in the adjuvant or neo-adjuvant setting,
             relapse must have occurred within 12 months to be considered prior therapy. Subject
             may have received prior immunotherapy.

          3. Subject has a tumor that carries a missense HRAS mutation. HRAS status may have been
             assessed either in blood, primary tumor tissue, recurrent or metastatic disease.

          4. Subject has consented to provide tumor slides (or tumor tissue blocks) for biomarker
             evaluation. If enrolment in the treatment portion of the study has taken place based
             on HRAS mutant status as assessed using a blood sample, tumor tissue will be used in
             part for confirmation of HRAS mutant tumor status. Confirmation of HRAS mutant status
             in tumor tissue is required for continuation of treatment. All treated subjects will
             be evaluated for safety.

          5. Subject has measurable disease according to RECIST v1.1.

          6. At least 2 weeks since the last systemic therapy regimen prior to enrolment. Subjects
             must have recovered to NCI CTCAE v. 4.03 &lt; Grade 2 from all acute toxicities
             (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and
             Investigator) or toxicity must be deemed irreversible by the Investigator.

          7. At least 2 weeks since last radiotherapy. If radiation was localized to the only site
             of measurable disease, there must be documentation of disease progression of the
             irradiated site. Subjects must have recovered from all acute toxicities from
             radiotherapy. Subjects may be on a daily dose of corticosteroids (≤ 20mg prednisone or
             equivalent), as part of their management from prior radiotherapy.

          8. ECOG (Eastern cooperative oncology group) performance status of 0 or 1.

          9. Acceptable liver function:

               1. Bilirubin less than 1.5 times upper limit of normal (x ULN); does not apply to
                  subjects with Gilbert's syndrome diagnosed as per institutional guidelines.

               2. AST Aspartate Amino-transferasa (SGOT) and ALT Aspartate-Alanina-transferasa
                  (SGPT) less than 3 x ULN; if liver metastases are present, then ≥ 5 x ULN is
                  allowed.

         10. Acceptable renal function with serum creatinine less than 1.5 x ULN or a calculated
             creatinine clearance ≥ 60 mL/min using the Cockcroft-Gault formula.

         11. Acceptable hematologic status:

               1. ANC (absolut neuthophil count) ≥ 1500 cells/μL.

               2. Platelet count ≥ 100,000/μL.

               3. Hemoglobin ≥ 9.0 g/dL.

         12. Female subjects must be either:

               1. Of non-child-bearing potential (surgically sterilized or at least 2 years
                  post-menopausal); or

               2. If of child-bearing potential, subject must use an adequate method of
                  contraception consisting of two-barrier method or one barrier method with a
                  spermicide or intrauterine device. Both females and male subjects with female
                  partners of child-bearing potential must agree to use an adequate method of
                  contraception for 2 weeks prior to screening, during, and at least 4 weeks after
                  last dose of trial medication. Female subjects must have a negative serum or
                  urine pregnancy test within 72 hours prior to start of trial medication.

               3. Not breast feeding at any time during the study.

         13. Written and voluntary informed consent for the treatment phase understood, signed and
             dated.

        Exclusion Criteria:

          1. Ongoing treatment with an anticancer agent not contemplated in this protocol.

          2. Prior treatment (at least 1 full treatment cycle) with an FTase inhibitor.

          3. Any history of clinically relevant coronary artery disease or myocardial infarction
             within the last 3 years, New York Heart Association (NYHA) grade III or greater
             congestive heart failure, cerebro-vascular attack within the prior year, or current
             serious cardiac arrhythmia requiring medication except atrial fibrillation.

          4. Known uncontrolled brain, leptomeningeal or epidural metastases (unless treated and
             well controlled for at least 4 weeks prior to Cycle 1 Day 1).

          5. Non-tolerable &gt; Grade 2 neuropathy or evidence of emerging or rapidly progressing
             neurological symptoms within 4 weeks of Cycle 1 Day 1. Non-tolerable grade 2
             toxicities are defined as those with moderate symptoms that the patient is not able to
             endure for the conduct of instrumental activities of daily life or that persists ≥ 7
             days.

          6. Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1,
             without complete recovery.

          7. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic
             therapy. Known infection with HIV, or an active infection with hepatitis B or
             hepatitis C.

          8. Subjects who have exhibited allergic reactions to tipifarnib or structural compounds
             similar to tipifarnib or to the drug product excipients. This includes
             hypersensitivity to imidazoles, such as clotrimazole, ketoconazole, miconazole and
             others in this drug class. Patients with hypersensitivity to these agents will be
             excluded from enrolment.

          9. Concomitant disease or condition that could interfere with the conduct of the study,
             or that would, in the opinion of the Investigator, pose an unacceptable risk to the
             subject in this study.

         10. The subject has legal incapacity or limited legal capacity.

         11. Significantly altered mental status that would limit the understanding or rendering of
             informed consent and compliance with the requirements of this protocol. Unwillingness
             or inability to comply with the study protocol for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Paz Ares, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital 12 de Octubre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Santiago Ponce, MD</last_name>
    <phone>+3493430206</phone>
    <email>sponceaix@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Pereira</last_name>
    <phone>+3493430206</phone>
    <email>epereira@gecp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jorge García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de los Lirios</name>
      <address>
        <city>Alcoy</city>
        <state>Alicante</state>
        <zip>03804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noemí Villanueva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Noemí Villanueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO-Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enric Carcereny, PhD</last_name>
      <phone>+ 93 430 20 06</phone>
      <email>ecarcereny@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Enric Carcereny</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO-Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ernest Nadal, phD</last_name>
      <phone>+34 32607744</phone>
      <email>esnadal@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Ernest Nadal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castelló de la Plana</city>
        <state>Castelló</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juana Campillo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juana Campillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa María Villatoro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rosa María Villatoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>43204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sergi Peralta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sergi Peralta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juana Oramas, MD</last_name>
      <email>joramas@huc.canarias.org</email>
    </contact>
    <investigator>
      <last_name>Juana Oramas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.U.Vall D´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susana Cedrés, MD</last_name>
      <phone>+34932746085</phone>
    </contact>
    <investigator>
      <last_name>Susana Cedrés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Clinic i Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noemí Reguart, MD</last_name>
      <phone>+34932275400</phone>
      <phone_ext>2811</phone_ext>
    </contact>
    <investigator>
      <last_name>Noemí Reguart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margarita Majem, MD-PhD</last_name>
    </contact>
    <investigator>
      <last_name>Margarita Majem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Carlos Villa, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Carlos Villa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona -H. Dr. Josep Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joaquim Bosch, MD</last_name>
      <phone>+34972225828</phone>
    </contact>
    <investigator>
      <last_name>Joaquim Bosch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Jaén</name>
      <address>
        <city>Jaén</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Laura Ortega, PhD</last_name>
      <phone>953 220 306</phone>
      <email>analauraortega@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ana Laura Ortega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Agustí</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Begoña Campos, MD</last_name>
      <phone>+34 982296000</phone>
      <email>begona.campo.balea2@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Begoña Campos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José Miguel Sánchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>José Miguel Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Santiago Ponce, MD</last_name>
      <phone>+34914692313</phone>
    </contact>
    <investigator>
      <last_name>Santiago Ponce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Cobo, MD</last_name>
      <phone>+34951290000</phone>
    </contact>
    <investigator>
      <last_name>Manuel Cobo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juan Coves, MD</last_name>
      <phone>+34871202000</phone>
      <phone_ext>1143</phone_ext>
      <email>jcoves@sll.es</email>
    </contact>
    <investigator>
      <last_name>Juan Coves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elvira del Barco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elvira del Barco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de La Macrena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Vicente, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Vicente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amelia Insa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amelia Insa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. General U. de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Aparisi</last_name>
      <phone>+34961972151</phone>
    </contact>
    <investigator>
      <last_name>Francisco Aparisi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Juan</last_name>
    </contact>
    <investigator>
      <last_name>Oscar Juan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.gecp.org</url>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tipifarnib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

